CMS Open Payments · Program Year 2024
Perspectum Diagnostics Ltd
Perspectum Diagnostics Ltd reported $1,216,687.79 across General Payments, Research, and Ownership to 148 physicians and teaching hospitals across 165 transactions.
- $1.2M Above-median payer
- All-tracks total
- 165 Above-median volume
- Transactions
- 148 Above-median reach
- Recipients
- −$142.5K
- General Payments vs PY2023
Perspectum Diagnostics Ltd reported $1,216,687.79 across all CMS Open Payments tracks (General + Research + Ownership) to 148 physicians and teaching hospitals in Program Year 2024 - ranking #575 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,078,972.92, averaging $8.2K per recipient.
How Perspectum Diagnostics Ltd's $1.2M all-tracks total breaks down
Perspectum Diagnostics Ltd's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
23/100
Total payments
F
21/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer perspectum-diagnostics-ltd Perspectum Diagnostics Ltd
$1.2M · #575/1,925 · 0.0% industry · PY2024
- TOT $1.2M
- RANK #575
- SHARE 0.0%
- TXN 165
- RCP 148
- CAT 4
- GEN $1.1M
- ΔGEN −$142.5K
- TOP1 43.0%
- PY 2024
Volume peers
Nearest volume peer: Spinal Surgical Strategies, Inc. ($1.2M)
Perspectum Diagnostics Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Perspectum Diagnostics Ltd's CMS-reported General Payments decreased by $142.5K (−11.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PERSPECTUM DIAGNOSTICS LTDPY2023: PERSPECTUM DIAGNOSTICS LTDPY2024: Perspectum Diagnostics Ltd. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,221,463.25
- PY2024
- $1,078,972.92
What the Data Shows for Perspectum Diagnostics Ltd
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Perspectum Diagnostics Ltd, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
117 transactions worth $1.1M make "Consulting Fee" the top general-payment category in the 4-category breakdown below, 99.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Perspectum Diagnostics Ltd's 4-category general-payment breakdown at $1.1M, 99.2% of the reported total.
Perspectum Diagnostics Ltd reports 4 general-payment categories - the top three are Consulting Fee (99.2%), Travel and Lodging (0.5%), and Food and Beverage (0.2%). The remaining 1 category make up 0.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Perspectum Diagnostics Ltd divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.1M | 117 | 99.2% |
| Travel and Lodging | $5.3K | 8 | 0.5% |
| Food and Beverage | $2.1K | 20 | 0.2% |
| Entertainment | $852.99 | 3 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,020,670.73 (94.6%) of $1,078,972.92 in this company's General Payments records across 22 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Perspectum Diagnostics Ltd
The five named recipients with the highest reported General Payments from this company
- 1
Meng Che Yeh
$463,892.12 across 26 reported transactions
- 2
Mukesh Harisinghani
$375,754.15 across 21 reported transactions
- 3
Fatih Akisik
$73,087.20 across 18 reported transactions
- 4
Naim Alkhouri
$59,937.26 across 12 reported transactions
- 5
Joel Brill
$48,000.00 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Perspectum Diagnostics Ltd's spend rank (#575 of 1,925, top 30% by spend) and concentration rank (#550 of 1,838, top 30% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- ICU Medical Inc : $55.8K total payments, HHI 3209
- Emergent BioSolutions Inc. : $6.8K total payments, HHI 3205
- Atlas Ocular, Inc : $35.4K total payments, HHI 3194
- HF Acquisition Co. LLC : $46.1K total payments, HHI 3193
- Okami Medical, Inc. : $92.0K total payments, HHI 3180
- Levita Magnetics International Corp. : $2.4K total payments, HHI 3174
- Perspectum Diagnostics Ltd (this company) : $1.1M total payments, HHI 3165
- Veru Inc. : $149.5K total payments, HHI 3151
- Merete Technologies, Inc : $72.1K total payments, HHI 3135
- Vifor (International) Ltd. : $132.0K total payments, HHI 3112
- Asklepios Biopharmaceutical Inc. : $7.6M total payments, HHI 3111
- Lumenis BE LTD : $35.5K total payments, HHI 3093
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Perspectum Diagnostics Ltd's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Perspectum Diagnostics Ltd.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Perspectum Diagnostics Ltd.
Showing 6 of 1,924 companies with CMS-reported payment data.
FX Shoulder Solutions, Inc
Agilent Technologies, Inc.
Braeburn Inc.
Anika Therapeutics, Inc.
MedShape, Inc.
Put this to use
Perspectum Diagnostics Ltd ranks #575 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Perspectum Diagnostics Ltd sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Perspectum Diagnostics Ltd. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.